KLOW

KLOW is GLOW plus KPV. GLOW is a 70mg vial containing BPC-157 10mg, TB-500 10mg and GHK-Cu 50mg; KLOW is an 80mg vial with the same three components at the same masses plus KPV 10mg. KPV is mechanistically the outlier of the four, its literature centres on PepT1-mediated uptake and NF-κB signalling in epithelial and colitis models rather than on angiogenesis, actin dynamics or copper transport. Researchers select KLOW over GLOW when a barrier or mucosal inflammation model is part of the design, and GLOW when it is not.

Each KLOW vial contains 80mg of lyophilised powder comprising KPV 10mg (Lys-Pro-Val, 342.4 g/mol), BPC-157 10mg (pentadecapeptide GEPPPGKPADDAGLV, 1419.53 g/mol), TB-500 10mg (thymosin beta 4, 43 residues, 4963.4 g/mol) and GHK-Cu 50mg (glycyl-L-histidyl-L-lysine copper(II) complex, 403.9 g/mol). The current batch is UKPL-609, with a third-party chromatographic purity assay published on the product page.

KPV is the tripeptide Lys-Pro-Val, 342.4 g/mol, the C-terminal fragment of alpha-melanocyte-stimulating hormone at residues 11 to 13. Its research interest lies in a transporter-gated mechanism rather than a receptor-mediated one. Dalmasso et al. (Gastroenterology, 2008, PMID 18061177) reported uptake through the di- and tripeptide transporter PepT1, which is expressed in the small intestine and induced in the colon during inflammation, associated with reduced NF-κB activation in human epithelial and immune cell lines. Viennois et al. (Cell Mol Gastroenterol Hepatol, 2016, PMID 27458604) reported the effect was absent in PepT1-knockout mice. Kannengiesser et al. (Inflamm Bowel Dis, 2008, PMID 18092346) reported activity in murine colitis models partly independent of MC1R.

No. There are no human trials of bare KPV; the published record is in-vitro work, including human cell lines, plus rodent models and reviews. The confusion usually arises from (CKPV)₂, a dimer of two KPV units joined by a cysteine linker, which is a chemically different molecule with its own investigational history and a partly MC1R-dependent mechanism. Findings for the dimer do not transfer to the bare tripeptide, and the stronger antimicrobial data in this area belong to the dimer rather than to KPV. Supplied for research use only.

No. No published study has examined KPV, BPC-157, TB-500 and GHK-Cu co-administered, at this ratio or any other, and no synergy among them has been demonstrated. Every mechanistic finding cited for klow peptides comes from work on one component in isolation, in different model systems and often at different scales. The blend should be treated as four separate compounds in one container, with controls designed on that basis rather than on an assumption of combined behaviour.

Every KLOW vial is supplied from batch UKPL-609, which was assayed by Janoshik Analytical on 26/10/2026 with the content of each component (KPV, BPC-157, TB-500 and GHK-Cu) reported individually. The certificate of analysis for this batch is published on the product page and can be independently checked at /verify. UK delivery is free on orders over £69, and orders placed before 3pm UK time on a working day are dispatched the same day.

One vial. Some suppliers sell KLOW as a kit of five or six separate vials to be reconstituted and combined by the researcher; the material here is a single pre-blended vial with all four components co-lyophilised, so there is one reconstitution step and one container to label and store. That is a factual format difference, not a purity or quality claim. A kit does retain one advantage a blend cannot match, namely independent control over each component's concentration.

UK Peptide Lab sells KLOW 80mg online as a single pre-blended research vial, dispatched from the UK. The current batch, UKPL-609, has its third-party certificate published with the listing. Orders placed before 3pm on a working day are dispatched the same day, and UK delivery is free over £69.

Janoshik Analytical quantified each component of batch UKPL-609 on 26 October 2026: KPV 11.06mg, BPC-157 11.35mg, TB-500 11.03mg and GHK-Cu 59.30mg per vial. The test measures content per component and does not report a single purity figure for the blend. The full certificate is published in the certificate section so you can check it before ordering.

Yes, for in-vitro laboratory research. KLOW is not a licensed medicine and is not approved for human or veterinary use, cosmetic use or any therapeutic purpose. Buyers must be 18 or over and confirm research-only use at checkout.

Choose KLOW if your model includes epithelial barrier, mucosal inflammation or colitis biology, because that is where the KPV literature sits. If it does not, the extra 10mg of KPV adds cost without a relevant mechanism, and GLOW is the closer fit. Use individual vials when you need a single-compound control arm.